US Patent 7615353 Tivozanib response prediction
Patent 7615353 was granted and assigned to AVEO Pharmaceuticals on November, 2009 by the United States Patent and Trademark Office.
All edits
Edits on 17 Sep, 2023
Golden AI
Edits made to:
Infobox (+4 properties)
Infobox
Patent Inventor Names
Bin Feng0
Jie Lin0
Murray Robinson0
Wenping Kathryn Sun0
Edits on 16 Sep, 2023
Golden AI
Edits made to:
Article (+332 characters)
Article
Patent abstract
A diagnostic method for predicting quantitatively whether a human tumor will be responsive or resistant (non-responsive) to treatment with the VEGF inhibitor, tivozanib (AV-951), is disclosed. The test is based on application of an algorithm to measurements of expression levels of the genes in a predictive gene set.
Edits on 25 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07615353 Tivozanib response prediction US Patent 7615353 Tivozanib response prediction
Infobox
Patent Number
076153530
Patent Number
76153530
Edits on 21 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 22 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
076153530
Date of Patent
November 10, 2009
0Patent Application Number
124981830
Date Filed
July 6, 2009
0Official Website
Patent Primary Examiner
Edits on 18 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 3 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07615353 Tivozanib response prediction
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07615353
Date of patent
November 10, 2009
Patent application number
12498183
Date Filed
July 6, 2009
Patent primary examiner
Find more entities like US Patent 7615353 Tivozanib response prediction
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.